Cover image of the article: Which Dose of Acetaminophen is Safe in Cirrhotic Patients?

Image Credit:84767

Which Dose of Acetaminophen is Safe in Cirrhotic Patients?

Authors

Hassan SoleimanpourHassan Soleimanpour ORCID1, Zahra ParsianZahra  Parsian ORCID2, Kavous Shahsavari NiaKavous  Shahsavari Nia ORCID3, Farzad Rahmani3, Seyed Moayed AlavianSeyed Moayed Alavian ORCID4, 5,*
1Emergency Medicine Research Team, Tabriz University of Medical Sciences, Tabriz, Iran
2Aging Research Institute, Tabriz University of Medical Sciences, Tabriz, Iran
3Road Traffic Injury Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
4Baqiyatallah Research Center for Gastroenterology and Liver Diseases, Baqiyatallah University of Medical Sciences, Tehran, Iran
5Tehran Hepatitis Center, Tehran, Iran
*Corresponding Author: Tehran Hepatitis Center, Tehran, IR Iran. Email: [email protected]

Hepatitis Monthly:Vol. 19, issue 5; e84767
Published online:May 28, 2019
Article type:Letter
Received:Sep 29, 2018
Accepted:May 12, 2019
How to Cite:Soleimanpour H, Parsian Z, Shahsavari Nia K, Rahmani F, Alavian SM. Which Dose of Acetaminophen is Safe in Cirrhotic Patients?. Hepat Mon. 2019;19(5):e84767. doi: https://doi.org/10.5812/hepatmon.84767

Dear Editor,
Pain management is crucial in all patients. Three main drug categories that control pain are opiates, non-steroidal anti-inflammatory drugs (NSAIDs), and acetaminophen. Opiates can cause sedation and constipation; they may also predispose cirrhotic patients to hepatic encephalopathy, so they are not favored in cirrhotic patients (1). NSAIDs increase the risk of gastrointestinal bleeding and renal injury, additively they decrease diuretics’ efficacy in cirrhotic patients (2). A well-known fact that acetaminophen is metabolized in liver and liver impairment ensues from acetaminophen overdose, creats an assumption that acetaminophen is not safe in these patients (1). The aim of this letter was to discuss the safe dose of acetaminophen in cirrhotic patients.
Acetaminophen at dose of 1 gram per day, for periods as short as 5 days does not even alter the half-life of acetaminophen in patients with hepatic failure (3). It might be necessary to reduce the dose in patients with liver disease especially those who are malnourished or underweight (4). Some studies that have evaluated the safe dose of acetaminophen in cirrhotic patients concluded that acetaminophen 2 grams per day is safe, and does not correlate with hepatic decompensation (5). This dose is found safe even for long term administration (1). Admittedly, this dose is not considered toxic in patients who have decompensated liver cirrhosis (6). Patients with alcoholic cirrhosis can also take up to 3 grams of acetaminophen each day (7). Doses as high as 4 grams per day taken for more than 5 days have not shown any toxic effects in patients with chronic liver disease (8). When this dose is administered to those with stable cirrhosis, its safety has been shown even for 13 days (9). It can thus be concluded that, acetaminophen is safe in cirrhotic patients at a dose of 2 - 3 grams per day for long term; and for short duration even 4 grams can be administered safely.

Footnotes

  • Authors’ Contribution:Study concept, design and supervision: Seyed Moayed Alavian and Hassan Soleimanpour; drafting of the manuscript: Zahra Parsian, Kavous Shahsavari Nia and Farzad Rahmani.

  • Conflicts of Interests:The authors declare no conflict of interest.

  • Funding/Support:This manuscript was funded by a grant (No: 5/d/100267 Date: 23-6-2018) from Vice Chancellor for Research and Technology, Tabriz University of Medical Sciences, Tabriz, Iran.

References

  • 1.
    Imani F, Motavaf M, Safari S, Alavian SM. The therapeutic use of analgesics in patients with liver cirrhosis: A literature review and evidence-based recommendations. Hepat Mon. 2014;14(10). e23539. [PubMed ID: 25477978]. [PubMed Central ID: PMC4250965]. https://doi.org/10.5812/hepatmon.23539.
  • 2.
    Soleimanpour M, Imani F, Safari S, Sanaie S, Soleimanpour H, Ameli H, et al. The role of non-steroidal anti-inflammatory drugs (NSAIDS) in the treatment of patients with hepatic disease: A review article. Anesth Pain Med. 2016;6(4). e37822. [PubMed ID: 27843779]. [PubMed Central ID: PMC5100664]. https://doi.org/10.5812/aapm.37822.
  • 3.
    Andreasen PB, Hutters L. Paracetamol (acetaminophen) clearance in patients with cirrhosis of the liver. Acta Med Scand Suppl. 1979;624:99-105. [PubMed ID: 284720].
  • 4.
    Hayward KL, Powell EE, Irvine KM, Martin JH. Can paracetamol (acetaminophen) be administered to patients with liver impairment? Br J Clin Pharmacol. 2016;81(2):210-22. [PubMed ID: 26460177]. [PubMed Central ID: PMC4833155]. https://doi.org/10.1111/bcp.12802.
  • 5.
    Riley TR, Smith JP. Preventive care in chronic liver disease. J Gen Intern Med. 1999;14(11):699-704. [PubMed ID: 10571719]. [PubMed Central ID: PMC1496761]. https://doi.org/10.1046/j.1525-1497.1999.11188.x.
  • 6.
    Lewis JH, Stine JG. Review article: Prescribing medications in patients with cirrhosis - a practical guide. Aliment Pharmacol Ther. 2013;37(12):1132-56. [PubMed ID: 23638982]. https://doi.org/10.1111/apt.12324.
  • 7.
    Lucena MI, Andrade RJ, Tognoni G, Hidalgo R, Sanchez de la Cuesta F; Spanish Collaborative Study Group on Therapeutic Management of Liver Diseases. Drug use for non-hepatic associated conditions in patients with liver cirrhosis. Eur J Clin Pharmacol. 2003;59(1):71-6. [PubMed ID: 12684727]. https://doi.org/10.1007/s00228-003-0586-2.
  • 8.
    Hirschfield GM, Kumagi T, Heathcote EJ. Preventative hepatology: Minimising symptoms and optimising care. Liver Int. 2008;28(7):922-34. [PubMed ID: 18783540]. https://doi.org/10.1111/j.1478-3231.2008.01816.x.
  • 9.
    Benson GD. Acetaminophen in chronic liver disease. Clin Pharmacol Ther. 1983;33(1):95-101. [PubMed ID: 6848304]. https://doi.org/10.1038/clpt.1983.14.

Copyright

Copyright © 2019, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.

Similar Articles

5
Aug
2020

Pain Management with Acetaminophen in Patients with Liver Diseases: A Review Article

Seyed Moayed Alavian,
Zahra Parsian,
Sarvin Sanaie,
Ata Mahmoodpoor,
Hassan Soleimanpour

Alavian SM, Parsian Z, Sanaie S, Mahmoodpoor A, Soleimanpour H. Pain Management with Acetaminophen in Patients with Liver Diseases: A Review Article. Shiraz E-Med J. 2020;22(8):e106900. doi: https://doi.org/10.5812/semj.106900

11
Oct
2014

The Therapeutic Use of Analgesics in Patients With Liver Cirrhosis: A Literature Review and Evidence-Based Recommendations

Farnad Imani,
Mahsa Motavaf,
Saeid Safari,
Seyed Moayed Alavian

Imani F, Motavaf M, Safari S, Alavian SM. The Therapeutic Use of Analgesics in Patients With Liver Cirrhosis: A Literature Review and Evidence-Based Recommendations. Hepat Mon. 2014;14(10):e23539. doi: https://doi.org/10.5812/hepatmon.23539

31
May
2011

Is the aspartate transaminase to platelet ratio index adequate for the assessment of liver fibrosis in patients with chronic liver disease?

Hadi Parsian

Parsian H. Is the aspartate transaminase to platelet ratio index adequate for the assessment of liver fibrosis in patients with chronic liver disease?. Hepat Mon. 2011;11(5):. doi:

30
Apr
2021

Plasma Concentration of Taurine Changes following Acetaminophen Overdose in Male Patients during Hospitalization

Mohammadreza Sattari,
Ali Ostadi,
Shokoufeh Hassani,
Zeynab Mazloumi,
Hamid Noshad,
Kayvan Mirnia
,et al.

Sattari M, Ostadi A, Hassani S, Mazloumi Z, Noshad H, et al. Plasma Concentration of Taurine Changes following Acetaminophen Overdose in Male Patients during Hospitalization. Iran J Pharm Res. 2021;20(2):e124324. doi: https://doi.org/10.22037/ijpr.2020.113698.14435

6
Mar
2016

Opioid Drugs in Patients With Liver Disease: A Systematic Review

Hassan Soleimanpour,
Saeid Safari,
Kavous Shahsavari Nia,
Sarvin Sanaie,
Seyed Moayed Alavian

Soleimanpour H, Safari S, Shahsavari Nia K, Sanaie S, Alavian SM. Opioid Drugs in Patients With Liver Disease: A Systematic Review. Hepat Mon. 2016;16(4):e32636. doi: https://doi.org/10.5812/hepatmon.32636

More by these authors

Hassan SoleimanpourPubMedScholar
Zahra ParsianPubMedScholar
Kavous Shahsavari NiaPubMedScholar
Farzad RahmaniPubMedScholar
Seyed Moayed AlavianPubMedScholar
Share
Cited by
Metrics